Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer

Identification of proteins associated with paclitaxel resistance of epithelial ovarian cancer using iTRAQ‑based proteomics

(2018) Yuanjing Wang et al.   Oncology Letters

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer

(2018) Emily Chan et al.   Oncotarget

Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis

(2017) Shosuke Kawanishi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Inflammation and Cancer: Extra- and Intracellular Determinants of Tumor-Associated Macrophages as Tumor Promoters

(2017) Gabor J. Szebeni et al.   MEDIATORS OF INFLAMMATION

Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells

(2017) Benoît Thibault et al.   Journal of Ovarian Research

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines

(2016) I Nakachi et al.   CTS-Clinical and Translational Science

Epithelial-to-endothelial transition and cancer stem cells: two cornerstones of vasculogenic mimicry in malignant tumors

(2016) Baocun Sun et al.   Oncotarget

The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours

(2015) S J Thomas et al.   BRITISH JOURNAL OF CANCER

Macrophages and Therapeutic Resistance in Cancer

(2015) Brian Ruffell et al.   CANCER CELL

The Src-Family Kinases Hck and Fgr Regulate Early Lipopolysaccharide-Induced Myeloid Cell Recruitment into the Lung and Their Ability To Secrete Chemokines

(2015) Paola Mazzi et al.   JOURNAL OF IMMUNOLOGY

A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer

(2015) Chantel Samardzija et al.   Molecular Cancer

Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling

(2015) JUAN XIAO et al.   Molecular Medicine Reports

Fyn is an important molecule in cancer pathogenesis and drug resistance

(2015) Daniel Elias et al.   PHARMACOLOGICAL RESEARCH

Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

(2015) Aaron Goldman et al.   Nature Communications

Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis

(2015) Sébastien Tabariès et al.   Oncotarget

Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status

(2015) Luigi Formisano et al.   Oncotarget

Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden

(2014) Khalid Abubaker et al.   BMC CANCER

The role of Src family kinases in growth and migration of glioma stem cells

(2014) XIAOSI HAN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death

(2013) James W. Hodge et al.   INTERNATIONAL JOURNAL OF CANCER

Regulation of Ovarian Cancer Stem Cells or Tumor-Initiating Cells

(2013) Mi Kwon et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ovarian cancer stem cells: Molecular concepts and relevance as therapeutic targets

(2013) Nuzhat Ahmed et al.   MOLECULAR ASPECTS OF MEDICINE

Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden

(2013) Khalid Abubaker et al.   Molecular Cancer

The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy

(2012) L. C. Hanker et al.   ANNALS OF ONCOLOGY

Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance

(2012) Nuzhat Ahmed et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Expression of c-Src and phospho-Src in epithelial ovarian carcinoma

(2012) Yong-Wen Huang et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Targeting the Yin and the Yang

(2012) Evan G. Gomes et al.   PANCREAS

Isolation and Characterization of Tumor Cells from the Ascites of Ovarian Cancer Patients: Molecular Phenotype of Chemoresistant Ovarian Tumors

(2012) Ardian Latifi et al.   PLoS One

Overcoming Challenges of Ovarian Cancer Stem Cells: Novel Therapeutic Approaches

(2012) Cristóbal Aguilar-Gallardo et al.   Stem Cell Reviews and Reports

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells

(2011) Deanna Teoh et al.   GYNECOLOGIC ONCOLOGY

Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation

(2011) A Kreutzman et al.   LEUKEMIA

Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors

(2010) John Araujo et al.   CANCER TREATMENT REVIEWS

Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition

(2010) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Wnt activity defines colon cancer stem cells and is regulated by the microenvironment

(2010) Louis Vermeulen et al.   NATURE CELL BIOLOGY

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

(2009) G E Konecny et al.   BRITISH JOURNAL OF CANCER

Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer

(2009) Jalid Sehouli et al.   JOURNAL OF SURGICAL ONCOLOGY

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH